Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Veklury | remdesivir | COVID-19 in hospitalized patients | Active | |||
Veklury | remdesivir | COVID-19 in non-hospitalized patients | Active | |||
Olumiant | baricitinib | Alopecia areata, severe | Active | |||
Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older | Active | |||
N/A | imiquimod | Gynecological cancers | Withdrawn | |||
TBC | clindamycin plus benzoyl peroxide and adapalene | acne vulgaris | Active | |||
Keytruda | pembrolizumab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | |||
TBC | ivosidenib | Acute myeloid leukemia (AML) | Active | |||
TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active |